NCT01807962 is a Phase 3 clinical trial of rapidocain and bethametsaone in Periarthritis, sponsored by Stephane Genevay.

Who is sponsoring NCT01807962?

NCT01807962 is sponsored by Stephane Genevay.

What drugs are being tested in NCT01807962?

Interventions in NCT01807962: rapidocain and bethametsaone, sterile saline.

What condition does NCT01807962 study?

NCT01807962 studies Periarthritis, Bursitis.

Is NCT01807962 still recruiting?

NCT01807962 is currently terminated. Last updated 7 June 2017.

Last reviewed 2017-06-07 · How we verify

NCT01807962

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Randomised Double Blind Controlled Trial of Injection of Local Anaesthetic and Corticosteroid Under Ultrasound Control in the Greater Trochanteric Pain Syndrome.

Terminated Phase 3 Last updated 7 June 2017

What this trial tests

Phase 3 trial testing rapidocain and bethametsaone in Periarthritis in 46 participants. Terminated before completion.

Timeline

1 November 2011

Primary endpoint
1 December 2015

1 December 2015

Quick facts

Lead sponsor	Stephane Genevay
Phase	Phase 3
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	treatment
Enrollment	46
Start date	1 November 2011
Primary completion	1 December 2015
Estimated completion	1 December 2015
Sites	1 location across Switzerland

Drugs / interventions tested

rapidocain and bethametsaone — full drug profile →
sterile saline — full drug profile →

Conditions studied

Periarthritis — all drugs for Periarthritis →
Bursitis — all drugs for Bursitis →

Sponsor

Stephane Genevay — full company profile →

Who can join

18 and older, any sex, with Periarthritis or Bursitis. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

The efficacy of ultrasound-guided injection with corticosteroid and local anaesthetic for GTPS.
Time frame: 4 weeks
Difference in pain intensity in the lateral hip region at 4 weeks between the 2 treatment groups, as measured by a NRS. Because the timing of the response to an infiltration is not well established we plan to examine pain both at 4 weeks, as well as longitudinally over 4 weeks(evolution of pain over time).

Sponsor's own description

We hypothesize that local ultrasound guided injection with corticosteroid and local anaesthetic are effective on the symptoms of GTPS.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01807962 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Stephane Genevay
Last refreshed: 7 June 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01807962.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing